A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy

Cognitive impairment, especially verbal episodic memory and executive function impairments, has been considered to be a possible adverse effect of aromatase inhibitors (AI). This phase III open-label study compared the impact of tamoxifen and AI on verbal episodic memory (Rey auditory verbal learnin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2015-08, Vol.152 (3), p.569-580
Hauptverfasser:	Le Rhun, Emilie, Delbeuck, Xavier, Lefeuvre-Plesse, Claudia, Kramar, Andrew, Skrobala, Emilie, Pasquier, Florence, Bonneterre, Jacques
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Androstadienes - adverse effects Androstadienes - therapeutic use Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use Breast cancer Breast Neoplasms - drug therapy Cancer Cancer patients Cancer research Cancer therapies Care and treatment Chemotherapy Chemotherapy, Adjuvant Clinical Trial Cognition Cognition Disorders - chemically induced Cognitive ability Comparative analysis Estrogens Female Humans Life Sciences Medicine Medicine & Public Health Memory - drug effects Menopause Middle Aged Nitriles - adverse effects Nitriles - therapeutic use Oncology Postmenopausal women Postmenopause Product development Psychomotor Performance - drug effects Quality of Life Side effects Studies Tamoxifen Tamoxifen - adverse effects Tamoxifen - therapeutic use Triazoles - adverse effects Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!